144 related articles for article (PubMed ID: 20863217)
21. Hemodialysis patients have plasmatic hypercoagulability and decreased fibrinolytic vulnerability: role of carbon monoxide.
Matika RW; Nielsen VG; Steinbrenner EB; Sussman AN; Madhrira M
ASAIO J; 2014; 60(6):716-21. PubMed ID: 25232771
[TBL] [Abstract][Full Text] [Related]
22. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
23. Homocysteine and renal disease.
van Guldener C; Robinson K
Semin Thromb Hemost; 2000; 26(3):313-24. PubMed ID: 11011849
[TBL] [Abstract][Full Text] [Related]
24. Endocrine-metabolic effects of l-carnitine in patients on regular dialysis treatment.
Albertazzi A; Capelli P; Di Paolo B; Pola P; Tondi P; Vaccario O
Proc Eur Dial Transplant Assoc; 1983; 19():302-7. PubMed ID: 6878245
[TBL] [Abstract][Full Text] [Related]
25. Carnitine treatment improved quality-of-life measure in a sample of Midwestern hemodialysis patients.
Steiber AL; Davis AT; Spry L; Strong J; Buss ML; Ratkiewicz MM; Weatherspoon LJ
JPEN J Parenter Enteral Nutr; 2006; 30(1):10-5. PubMed ID: 16387893
[TBL] [Abstract][Full Text] [Related]
26. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
27. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial.
Malaguarnera M; Gargante MP; Russo C; Antic T; Vacante M; Malaguarnera M; Avitabile T; Li Volti G; Galvano F
Am J Gastroenterol; 2010 Jun; 105(6):1338-45. PubMed ID: 20068559
[TBL] [Abstract][Full Text] [Related]
28. Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) level in hemodialysis patients and parameters affecting that level.
Ulusoy S; Ozkan G; Menteşe A; Yavuz A; Karahan SC; Sümer AU
Clin Biochem; 2012 Nov; 45(16-17):1444-9. PubMed ID: 22874483
[TBL] [Abstract][Full Text] [Related]
29. Effects of L-carnitine on oxidative stress responses in patients with renal disease.
Fatouros IG; Douroudos I; Panagoutsos S; Pasadakis P; Nikolaidis MG; Chatzinikolaou A; Sovatzidis A; Michailidis Y; Jamurtas AZ; Mandalidis D; Taxildaris K; Vargemezis V
Med Sci Sports Exerc; 2010 Oct; 42(10):1809-18. PubMed ID: 20216464
[TBL] [Abstract][Full Text] [Related]
30. [Carnitine metabolism in chronic kidney failure].
Fiorini F; Patrone E; Castellucci A
Clin Ter; 1992 Jan; 140(1 Pt 2):31-4. PubMed ID: 1559320
[TBL] [Abstract][Full Text] [Related]
31. Ketogenic and antiketogenic effects of L-carnitine in hemodialysis patients.
Wanner C; Wieland H; Wäckerle B; Boeckle H; Schollmeyer P; Hörl WH
Kidney Int Suppl; 1989 Nov; 27():S264-8. PubMed ID: 2636668
[TBL] [Abstract][Full Text] [Related]
32. L-Carnitine ameliorates glycerol-induced myoglobinuric acute renal failure in rats.
Ustundag S; Sen S; Yalcin O; Ciftci S; Demirkan B; Ture M
Ren Fail; 2009; 31(2):124-33. PubMed ID: 19212909
[TBL] [Abstract][Full Text] [Related]
33. L-carnitine in dialysed patients: the choice of dosage regimen.
Berard E; Iordache A; Barrillon D; Bayle J
Int J Clin Pharmacol Res; 1995; 15(3):127-33. PubMed ID: 8847154
[TBL] [Abstract][Full Text] [Related]
34. Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients.
Alvares Delfino VD; de Andrade Vianna AC; Mocelin AJ; Barbosa DS; Mise RA; Matsuo T
Nutrition; 2007 Mar; 23(3):242-7. PubMed ID: 17321110
[TBL] [Abstract][Full Text] [Related]
35. [Effects of L-carnitine on erythropoiesis and blood platelet aggregation in patients with chronic renal failure treated with hemodialysis].
Kalinowski M; Popławski A; Mazerska M; Daniluk A
Pol Merkur Lekarski; 1999 Feb; 6(32):76-8. PubMed ID: 10337176
[TBL] [Abstract][Full Text] [Related]
36. Advances in carnitine in chronic uremia.
Guarnieri G; Biolo G; Vinci P; Massolino B; Barazzoni R
J Ren Nutr; 2007 Jan; 17(1):23-9. PubMed ID: 17198928
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
[TBL] [Abstract][Full Text] [Related]
38. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
39. The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure.
Madsen T; Schmidt EB; Christensen JH
J Ren Nutr; 2007 Jul; 17(4):258-63. PubMed ID: 17586424
[TBL] [Abstract][Full Text] [Related]
40. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.
Snaedal S; Heimbürger O; Qureshi AR; Danielsson A; Wikström B; Fellström B; Fehrman-Ekholm I; Carrero JJ; Alvestrand A; Stenvinkel P; Bárány P
Am J Kidney Dis; 2009 Jun; 53(6):1024-33. PubMed ID: 19394732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
